<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05049551</url>
  </required_header>
  <id_info>
    <org_study_id>21-09</org_study_id>
    <nct_id>NCT05049551</nct_id>
  </id_info>
  <brief_title>Thyroid Uptake Quantification on a New Generation of Gamma Camera</brief_title>
  <acronym>QUANTHYC</acronym>
  <official_title>Quantitative Analysis of 99mTc-Pertechnetate Thyroid Uptake With a Large Field CZT Gamma Camera: Feasibility and Comparison Between SPECT/CT and Planar Acquisitions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Princesse Grace</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Princesse Grace</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the potential of a new large field CZT&#xD;
      gamma camera to estimate the thyroid uptake (TU) on Single photon emission computed&#xD;
      tomography (SPECT) and SPECT/CT images in comparison with standard planar scintigraphy.&#xD;
&#xD;
      The secondary objective is to analyze the diagnostic contribution of SPECT/CT imaging.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Planar and SPECT/CT scintigraphy will be performed on a new generation large field CZT gamma&#xD;
      camera and thyroid uptake (TU) value will be calculated on planar acquisition for 23&#xD;
      consecutive patients referred in our department for hyperthyroidism.&#xD;
&#xD;
      With a quantitative approach using attenuation, scatter correction and iterative algorithm&#xD;
      with resolution recovery we will have the possibility to calculate the TU value with SPECT or&#xD;
      SPECT/CT acquisitions.&#xD;
&#xD;
      Our primary objective will be to evaluate the potential of a new large field CZT gamma camera&#xD;
      to estimate the thyroid uptake on SPECT (Tomography without attenuation correction) and&#xD;
      SPECT/CT (tomography with attenuation correction) acquisitions compared with standard planar&#xD;
      scintigraphy as a gold standard.&#xD;
&#xD;
      The secondary objective will be to analyze the diagnostic contribution of SPECT/CT images.&#xD;
&#xD;
      To established this study it will be necessary to introduce cross-calibration factors&#xD;
      performed from a thyroid phantom, for planar and SPECT acquisitions, to estimate the thyroid&#xD;
      uptake values.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 30, 2019</start_date>
  <completion_date type="Actual">September 7, 2020</completion_date>
  <primary_completion_date type="Actual">June 22, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Thyroid uptake</measure>
    <time_frame>Inclusion</time_frame>
    <description>Quantification of thyroid uptake</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SPECT/CT</measure>
    <time_frame>Inclusion</time_frame>
    <description>Diagnostic contribution of SPECT/CT</description>
  </secondary_outcome>
  <enrollment type="Actual">23</enrollment>
  <condition>Hyperthyroidism</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Twenty-three consecutive participants referred in our nuclear medicine department for&#xD;
        hyperthyroidism&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hyperthyroidism confirmed by blood test (TSH) and thyroid ultrasound&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre Hospitalier Princesse Grace</name>
      <address>
        <city>Monaco</city>
        <zip>98000</zip>
        <country>Monaco</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Monaco</country>
  </location_countries>
  <reference>
    <citation>Ritt P, Vija H, Hornegger J, Kuwert T. Absolute quantification in SPECT. Eur J Nucl Med Mol Imaging. 2011 May;38 Suppl 1:S69-77. doi: 10.1007/s00259-011-1770-8. Epub 2011 Apr 12. Review.</citation>
    <PMID>21484383</PMID>
  </reference>
  <reference>
    <citation>Gnesin S, Leite Ferreira P, Malterre J, Laub P, Prior JO, Verdun FR. Phantom Validation of Tc-99m Absolute Quantification in a SPECT/CT Commercial Device. Comput Math Methods Med. 2016;2016:4360371. doi: 10.1155/2016/4360371. Epub 2016 Dec 14.</citation>
    <PMID>28096891</PMID>
  </reference>
  <reference>
    <citation>Giovanella L, Avram AM, Iakovou I, Kwak J, Lawson SA, Lulaj E, Luster M, Piccardo A, Schmidt M, Tulchinsky M, Verburg FA, Wolin E. EANM practice guideline/SNMMI procedure standard for RAIU and thyroid scintigraphy. Eur J Nucl Med Mol Imaging. 2019 Nov;46(12):2514-2525. doi: 10.1007/s00259-019-04472-8. Epub 2019 Aug 7.</citation>
    <PMID>31392371</PMID>
  </reference>
  <reference>
    <citation>Mariani G, Tonacchera M, Grosso M, Orsolini F, Vitti P, Strauss HW. The Role of Nuclear Medicine in the Clinical Management of Benign Thyroid Disorders, Part 1: Hyperthyroidism. J Nucl Med. 2021 Mar;62(3):304-312. doi: 10.2967/jnumed.120.243170. Epub 2020 Oct 2. Review.</citation>
    <PMID>33008929</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 9, 2021</study_first_submitted>
  <study_first_submitted_qc>September 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2021</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>thyroid</keyword>
  <keyword>uptake</keyword>
  <keyword>quantification</keyword>
  <keyword>CZT</keyword>
  <keyword>Planar</keyword>
  <keyword>SPECT/CT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperthyroidism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

